An Open-label, Phase 1 Study to Individually Characterize the Food Effect, the Drug-Drug Interaction Effect of OAT Inhibition, and the Drug-Drug Interaction Effect of P-glycoprotein Inhibition on the Pharmacokinetics of MK-8527 in Healthy Adult Participants
Merck Sharp & Dohme LLC
Summary
Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults. The goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.
Eligibility
- Age range
- 18–55 years
- Sex
- All
- Healthy volunteers
- Yes
Inclusion Criteria: * Be in good health * Has a body mass index (BMI) between 18 and 32 kg/m\^2, inclusive Exclusion Criteria: * Has an estimated glomerular filtration rate (eGFR) ≤90 mL/min/1.73 m\^2 * Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered…
Interventions
- DrugMK-8527
Oral tablet
- DrugProbenecid
Oral tablet
- DrugItraconazole
Oral solution
Location
- Fortrea Clinical Research Unit Inc ( Site 0001)Daytona Beach, Florida